Armata’s phage product candidates aim to address areas of significant unmet clinical need, by targeting key antibiotic-resistant bacteria including those on the World Health Organization’s global priority pathogens list. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Proprietary synthetic phage candidates designed to target an undisclosed infectious disease agent are being developed in partnership with Merck. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage-specific GMP manufacturing.
| Pathogen | Indications | Discovery | Preclinical | Phase 1 | Phase 2 |
|---|---|---|---|---|---|
| Staphylococcus aureus | Bacteremia |
AP-SA01
|
|||
| Pseudomonas aeruginosa | Respiratory | AP-PA02 |
|||
| Undisclosed | Undisclosed |
Partnered
 |
| Pathogen Indications |
Phase | Partner |
|---|---|---|
| S. aureus Bacteremia |
Phase 1/2 (AP-SA01) | |
| P. aeruginosa Respiratory |
Preclinical | |
| Undisclosed Undisclosed |
Discovery | |
